Download Zipped Introduced WordPerfect HB0143.ZIP
[Status][Bill Documents][Fiscal Note][Bills Directory]

H.B. 143

             1     

CONTROLLED SUBSTANCES AMENDMENTS -

             2     
SUDA CONTROLS

             3     
2007 GENERAL SESSION

             4     
STATE OF UTAH

             5     
Chief Sponsor: Neil A. Hansen

             6     
Senate Sponsor: ____________

             7     
             8      LONG TITLE
             9      General Description:
             10          This bill modifies Title 58, Chapter 37, Utah Controlled Substances Act, by amending
             11      the regulation of retail sales of products used to make methamphetamine.
             12      Highlighted Provisions:
             13          This bill:
             14          .    establishes ephedrine, pseudoephedrine, norpseudoephedrine, and
             15      phenylpropanolamine as Schedule V controlled substances;
             16          .    authorizes preparations of ephedrine, pseudoephedrine, norpseudoephedrine, and
             17      phenylpropanolamine intended for lawful use in the diagnosis, cure, mitigation,
             18      treatment, or prevention of disease to be purchased, sold, or transferred without a
             19      prescription if:
             20              .    dispensed by a person licensed under Title 58, Chapter 17b, Pharmacy Practice
             21      Act; and
             22              .    recorded in the Division of Occupational and Professional Licensure's
             23      controlled substance database; and
             24          .    authorizes the division to establish rules for reporting transactions of products
             25      containing ephedrine, pseudoephedrine, norpseudoephedrine, and
             26      phenylpropanolamine.
             27      Monies Appropriated in this Bill:



             28          None
             29      Other Special Clauses:
             30          This bill takes effect on January 1, 2008.
             31      Utah Code Sections Affected:
             32      AMENDS:
             33          58-37-2, as last amended by Chapter 8, Laws of Utah 2006
             34          58-37-4, as last amended by Chapter 8, Laws of Utah 2006
             35          58-37-7.5, as last amended by Chapter 46, Laws of Utah 2006
             36     
             37      Be it enacted by the Legislature of the state of Utah:
             38          Section 1. Section 58-37-2 is amended to read:
             39           58-37-2. Definitions.
             40          (1) As used in this chapter:
             41          (a) "Administer" means the direct application of a controlled substance, whether by
             42      injection, inhalation, ingestion, or any other means, to the body of a patient or research subject
             43      by:
             44          (i) a practitioner or, in his presence, by his authorized agent; or
             45          (ii) the patient or research subject at the direction and in the presence of the
             46      practitioner.
             47          (b) "Agent" means an authorized person who acts on behalf of or at the direction of a
             48      manufacturer, distributor, or practitioner but does not include a motor carrier, public
             49      warehouseman, or employee of any of them.
             50          (c) "Consumption" means ingesting or having any measurable amount of a controlled
             51      substance in a person's body, but this Subsection (1)(c) does not include the metabolite of a
             52      controlled substance.
             53          (d) "Continuing criminal enterprise" means any individual, sole proprietorship,
             54      partnership, corporation, business trust, association, or other legal entity, and any union or
             55      groups of individuals associated in fact although not a legal entity, and includes illicit as well
             56      as licit entities created or maintained for the purpose of engaging in conduct which constitutes
             57      the commission of episodes of activity made unlawful by Title 58, Chapters 37, 37a, 37b, 37c,
             58      or 37d, which episodes are not isolated, but have the same or similar purposes, results,


             59      participants, victims, methods of commission, or otherwise are interrelated by distinguishing
             60      characteristics. Taken together, the episodes shall demonstrate continuing unlawful conduct
             61      and be related either to each other or to the enterprise.
             62          (e) "Control" means to add, remove, or change the placement of a drug, substance, or
             63      immediate precursor under Section 58-37-3 .
             64          (f) (i) "Controlled substance" means a drug or substance included in Schedules I, II, III,
             65      IV, or V of Section 58-37-4 , and also includes a drug or substance included in Schedules I, II,
             66      III, IV, or V of the federal Controlled Substances Act, Title II, P.L. 91-513, or any controlled
             67      substance analog.
             68          (ii) "Controlled substance" does not include:
             69          (A) distilled spirits, wine, or malt beverages, as those terms are defined or used in Title
             70      32A, Alcoholic Beverage Control Act, regarding tobacco or food; or
             71          [(B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             72      prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine,
             73      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             74      transferred, or furnished as an over-the-counter medication without prescription; or]
             75          [(C)] (B) dietary supplements, vitamins, minerals, herbs, or other similar substances
             76      including concentrates or extracts, which are not otherwise regulated by law, which may
             77      contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules
             78      adopted pursuant to Title 63, Chapter 46a, Utah Administrative Rulemaking Act.
             79          (g) (i) "Controlled substance analog" means a substance the chemical structure of
             80      which is substantially similar to the chemical structure of a controlled substance listed in
             81      Schedules I and II of Section 58-37-4 , or in Schedules I and II of the federal Controlled
             82      Substances Act, Title II, P.L. 91-513:
             83          (A) which has a stimulant, depressant, or hallucinogenic effect on the central nervous
             84      system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central
             85      nervous system of controlled substances in the schedules set forth in Subsection (1)(f); or
             86          (B) which, with respect to a particular individual, is represented or intended to have a
             87      stimulant, depressant, or hallucinogenic effect on the central nervous system substantially
             88      similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of
             89      controlled substances in the schedules set forth in this Subsection (1).


             90          (ii) "Controlled substance analog" does not include:
             91          (A) a controlled substance currently scheduled in Schedules I through V of Section
             92      58-37-4 ;
             93          (B) a substance for which there is an approved new drug application;
             94          (C) a substance with respect to which an exemption is in effect for investigational use
             95      by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 366,
             96      to the extent the conduct with respect to the substance is permitted by the exemption;
             97          (D) any substance to the extent not intended for human consumption before an
             98      exemption takes effect with respect to the substance; or
             99          [(E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             100      prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine,
             101      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             102      transferred, or furnished as an over-the-counter medication without prescription; or]
             103          [(F)] (E) dietary supplements, vitamins, minerals, herbs, or other similar substances
             104      including concentrates or extracts, which are not otherwise regulated by law, which may
             105      contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules
             106      adopted pursuant to Title 63, Chapter 46a, Utah Administrative Rulemaking Act.
             107          (h) "Conviction" means a determination of guilt by verdict, whether jury or bench, or
             108      plea, whether guilty or no contest, for any offense proscribed by Title 58, Chapters 37, 37a,
             109      37b, 37c, or 37d, or for any offense under the laws of the United States and any other state
             110      which, if committed in this state, would be an offense under Title 58, Chapters 37, 37a, 37b,
             111      37c, or 37d.
             112          (i) "Counterfeit substance" means:
             113          (i) any substance or container or labeling of any substance that without authorization
             114      bears the trademark, trade name, or other identifying mark, imprint, number, device, or any
             115      likeness of them, of a manufacturer, distributor, or dispenser other than the person or persons
             116      who in fact manufactured, distributed, or dispensed the substance which falsely purports to be a
             117      controlled substance distributed by, any other manufacturer, distributor, or dispenser; or
             118          (ii) any substance that is represented to be a controlled substance.
             119          (j) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a
             120      controlled substance or a listed chemical, whether or not an agency relationship exists.


             121          (k) "Department" means the Department of Commerce.
             122          (l) "Depressant or stimulant substance" means:
             123          (i) a drug which contains any quantity of barbituric acid or any of the salts of barbituric
             124      acid;
             125          (ii) a drug which contains any quantity of:
             126          (A) amphetamine or any of its optical isomers;
             127          (B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or
             128          (C) any substance which the Secretary of Health and Human Services or the Attorney
             129      General of the United States after investigation has found and by regulation designated
             130      habit-forming because of its stimulant effect on the central nervous system;
             131          (iii) lysergic acid diethylamide; or
             132          (iv) any drug which contains any quantity of a substance which the Secretary of Health
             133      and Human Services or the Attorney General of the United States after investigation has found
             134      to have, and by regulation designated as having, a potential for abuse because of its depressant
             135      or stimulant effect on the central nervous system or its hallucinogenic effect.
             136          (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an
             137      ultimate user pursuant to the lawful order or prescription of a practitioner, and includes
             138      distributing to, leaving with, giving away, or disposing of that substance as well as the
             139      packaging, labeling, or compounding necessary to prepare the substance for delivery.
             140          (n) "Dispenser" means a pharmacist who dispenses a controlled substance.
             141          (o) "Distribute" means to deliver other than by administering or dispensing a controlled
             142      substance or a listed chemical.
             143          (p) "Distributor" means a person who distributes controlled substances.
             144          (q) "Division" means the Division of Occupational and Professional Licensing created
             145      in Section 58-1-103 .
             146          (r) "Drug" means:
             147          (i) articles recognized in the official United States Pharmacopoeia, Official
             148      Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
             149      supplement to any of them;
             150          (ii) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention
             151      of disease in man or other animals;


             152          (iii) articles, other than food, intended to affect the structure or function of man or
             153      other animals; and
             154          (iv) articles intended for use as a component of any articles specified in Subsection
             155      (1)(r)(i), (ii), or (iii); but does not include devices or their components, parts, or accessories.
             156          (s) "Drug dependent person" means any individual who unlawfully and habitually uses
             157      any controlled substance to endanger the public morals, health, safety, or welfare, or who is so
             158      dependent upon the use of controlled substances as to have lost the power of self-control with
             159      reference to his dependency.
             160          (t) "Food" means:
             161          (i) any nutrient or substance of plant, mineral, or animal origin other than a drug as
             162      specified in this chapter, and normally ingested by human beings; and
             163          (ii) foods for special dietary uses as exist by reason of a physical, physiological,
             164      pathological, or other condition including but not limited to the conditions of disease,
             165      convalescence, pregnancy, lactation, allergy, hypersensitivity to food, underweight, and
             166      overweight; uses for supplying a particular dietary need which exist by reason of age including
             167      but not limited to the ages of infancy and childbirth, and also uses for supplementing and for
             168      fortifying the ordinary or unusual diet with any vitamin, mineral, or other dietary property for
             169      use of a food. Any particular use of a food is a special dietary use regardless of the nutritional
             170      purposes.
             171          (u) "Immediate precursor" means a substance which the Attorney General of the United
             172      States has found to be, and by regulation designated as being, the principal compound used or
             173      produced primarily for use in the manufacture of a controlled substance, or which is an
             174      immediate chemical intermediary used or likely to be used in the manufacture of a controlled
             175      substance, the control of which is necessary to prevent, curtail, or limit the manufacture of the
             176      controlled substance.
             177          (v) "Indian" means a member of an Indian tribe.
             178          (w) "Indian religion" means any religion:
             179          (i) the origin and interpretation of which is from within a traditional Indian culture or
             180      community; and
             181          (ii) which is practiced by Indians.
             182          (x) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or


             183      community of Indians, including any Alaska Native village, which is legally recognized as
             184      eligible for and is consistent with the special programs, services, and entitlements provided by
             185      the United States to Indians because of their status as Indians.
             186          (y) "Manufacture" means the production, preparation, propagation, compounding, or
             187      processing of a controlled substance, either directly or indirectly by extraction from substances
             188      of natural origin, or independently by means of chemical synthesis or by a combination of
             189      extraction and chemical synthesis.
             190          (z) "Manufacturer" includes any person who packages, repackages, or labels any
             191      container of any controlled substance, except pharmacists who dispense or compound
             192      prescription orders for delivery to the ultimate consumer.
             193          (aa) "Marijuana" means all species of the genus cannabis and all parts of the genus,
             194      whether growing or not; the seeds of it; the resin extracted from any part of the plant; and every
             195      compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or
             196      resin. The term does not include the mature stalks of the plant, fiber produced from the stalks,
             197      oil or cake made from the seeds of the plant, any other compound, manufacture, salt,
             198      derivative, mixture, or preparation of the mature stalks, except the resin extracted from them,
             199      fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination. Any
             200      synthetic equivalents of the substances contained in the plant cannabis sativa or any other
             201      species of the genus cannabis which are chemically indistinguishable and pharmacologically
             202      active are also included.
             203          (bb) "Money" means officially issued coin and currency of the United States or any
             204      foreign country.
             205          (cc) "Narcotic drug" means any of the following, whether produced directly or
             206      indirectly by extraction from substances of vegetable origin, or independently by means of
             207      chemical synthesis, or by a combination of extraction and chemical synthesis:
             208          (i) opium, coca leaves, and opiates;
             209          (ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves, or
             210      opiates;
             211          (iii) opium poppy and poppy straw; or
             212          (iv) a substance, and any compound, manufacture, salt, derivative, or preparation of the
             213      substance, which is chemically identical with any of the substances referred to in Subsection


             214      (1)(cc)(i), (ii), or (iii), except narcotic drug does not include decocainized coca leaves or
             215      extracts of coca leaves which do not contain cocaine or ecgonine.
             216          (dd) "Negotiable instrument" means documents, containing an unconditional promise
             217      to pay a sum of money, which are legally transferable to another party by endorsement or
             218      delivery.
             219          (ee) "Opiate" means any drug or other substance having an addiction-forming or
             220      addiction-sustaining liability similar to morphine or being capable of conversion into a drug
             221      having addiction-forming or addiction-sustaining liability.
             222          (ff) "Opium poppy" means the plant of the species papaver somniferum L., except the
             223      seeds of the plant.
             224          (gg) "Person" means any corporation, association, partnership, trust, other institution or
             225      entity or one or more individuals.
             226          (hh) "Poppy straw" means all parts, except the seeds, of the opium poppy, after
             227      mowing.
             228          (ii) "Possession" or "use" means the joint or individual ownership, control, occupancy,
             229      holding, retaining, belonging, maintaining, or the application, inhalation, swallowing, injection,
             230      or consumption, as distinguished from distribution, of controlled substances and includes
             231      individual, joint, or group possession or use of controlled substances. For a person to be a
             232      possessor or user of a controlled substance, it is not required that he be shown to have
             233      individually possessed, used, or controlled the substance, but it is sufficient if it is shown that
             234      the person jointly participated with one or more persons in the use, possession, or control of
             235      any substances with knowledge that the activity was occurring, or the controlled substance is
             236      found in a place or under circumstances indicating that the person had the ability and the intent
             237      to exercise dominion and control over it.
             238          (jj) "Practitioner" means a physician, dentist, veterinarian, pharmacist, scientific
             239      investigator, pharmacy, hospital, or other person licensed, registered, or otherwise permitted to
             240      distribute, dispense, conduct research with respect to, administer, or use in teaching or
             241      chemical analysis a controlled substance in the course of professional practice or research in
             242      this state.
             243          (kk) "Prescribe" means to issue a prescription orally or in writing.
             244          (ll) "Prescription" means an order issued by a licensed practitioner, in the course of that


             245      practitioner's professional practice, for a controlled substance, other drug, or device which it
             246      dispenses or administers for use by a patient or an animal. The order may be issued by word of
             247      mouth, written document, telephone, facsimile transmission, computer, or other electronic
             248      means of communication as defined by rule.
             249          (mm) "Production" means the manufacture, planting, cultivation, growing, or
             250      harvesting of a controlled substance.
             251          (nn) "Securities" means any stocks, bonds, notes, or other evidences of debt or of
             252      property.
             253          (oo) "State" means the state of Utah.
             254          (pp) "Ultimate user" means any person who lawfully possesses a controlled substance
             255      for his own use, for the use of a member of his household, or for administration to an animal
             256      owned by him or a member of his household.
             257          (2) If a term used in this chapter is not defined, the definition and terms of Title 76,
             258      Utah Criminal Code, shall apply.
             259          Section 2. Section 58-37-4 is amended to read:
             260           58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings
             261      required -- Specific substances included in schedules.
             262          (1) There are established five schedules of controlled substances known as Schedules I,
             263      II, III, IV, and V which shall consist of substances listed in this section.
             264          (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
             265      the official name, common or usual name, chemical name, or brand name designated:
             266          (a) Schedule I:
             267          (i) Unless specifically excepted or unless listed in another schedule, any of the
             268      following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
             269      ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
             270      chemical designation:
             271          (A) Acetyl-alpha-methylfentanyl
             272      (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
             273          (B) Acetylmethadol;
             274          (C) Allylprodine;
             275          (D) Alphacetylmethadol, except levo-alphacetylmethadol also known as


             276      levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
             277          (E) Alphameprodine;
             278          (F) Alphamethadol;
             279          (G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
             280      propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
             281          (H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
             282      piperidinyl]-N-phenylpropanamide);
             283          (I) Benzethidine;
             284          (J) Betacetylmethadol;
             285          (K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
             286      piperidinyl]-N-phenylpropanamide);
             287          (L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
             288      phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
             289          (M) Betameprodine;
             290          (N) Betamethadol;
             291          (O) Betaprodine;
             292          (P) Clonitazene;
             293          (Q) Dextromoramide;
             294          (R) Diampromide;
             295          (S) Diethylthiambutene;
             296          (T) Difenoxin;
             297          (U) Dimenoxadol;
             298          (V) Dimepheptanol;
             299          (W) Dimethylthiambutene;
             300          (X) Dioxaphetyl butyrate;
             301          (Y) Dipipanone;
             302          (Z) Ethylmethylthiambutene;
             303          (AA) Etonitazene;
             304          (BB) Etoxeridine;
             305          (CC) Furethidine;
             306          (DD) Hydroxypethidine;


             307          (EE) Ketobemidone;
             308          (FF) Levomoramide;
             309          (GG) Levophenacylmorphan;
             310          (HH) Morpheridine;
             311          (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
             312          (JJ) Noracymethadol;
             313          (KK) Norlevorphanol;
             314          (LL) Normethadone;
             315          (MM) Norpipanone;
             316          (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
             317      propanamide;
             318          (OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
             319          (PP) Phenadoxone;
             320          (QQ) Phenampromide;
             321          (RR) Phenomorphan;
             322          (SS) Phenoperidine;
             323          (TT) Piritramide;
             324          (UU) Proheptazine;
             325          (VV) Properidine;
             326          (WW) Propiram;
             327          (XX) Racemoramide;
             328          (YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
             329          (ZZ) Tilidine;
             330          (AAA) Trimeperidine;
             331          (BBB) 3-methylfentanyl, including the optical and geometric isomers
             332      (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
             333          (CCC) 3-methylthiofentanyl
             334      (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
             335          (ii) Unless specifically excepted or unless listed in another schedule, any of the
             336      following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
             337      salts, isomers, and salts of isomers is possible within the specific chemical designation:


             338          (A) Acetorphine;
             339          (B) Acetyldihydrocodeine;
             340          (C) Benzylmorphine;
             341          (D) Codeine methylbromide;
             342          (E) Codeine-N-Oxide;
             343          (F) Cyprenorphine;
             344          (G) Desomorphine;
             345          (H) Dihydromorphine;
             346          (I) Drotebanol;
             347          (J) Etorphine (except hydrochloride salt);
             348          (K) Heroin;
             349          (L) Hydromorphinol;
             350          (M) Methyldesorphine;
             351          (N) Methylhydromorphine;
             352          (O) Morphine methylbromide;
             353          (P) Morphine methylsulfonate;
             354          (Q) Morphine-N-Oxide;
             355          (R) Myrophine;
             356          (S) Nicocodeine;
             357          (T) Nicomorphine;
             358          (U) Normorphine;
             359          (V) Pholcodine; and
             360          (W) Thebacon.
             361          (iii) Unless specifically excepted or unless listed in another schedule, any material,
             362      compound, mixture, or preparation which contains any quantity of the following hallucinogenic
             363      substances, or which contains any of their salts, isomers, and salts of isomers when the
             364      existence of the salts, isomers, and salts of isomers is possible within the specific chemical
             365      designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and
             366      geometric isomers:
             367          (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
             368      .-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; .-ET; and AET;


             369          (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
             370      4-bromo-2,5-dimethoxy-.-methylphenethylamine; 4-bromo-2,5-DMA;
             371          (C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
             372      2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
             373          (D) 2,5-dimethoxyamphetamine, some trade or other names:
             374      2,5-dimethoxy-.-methylphenethylamine; 2,5-DMA;
             375          (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
             376          (F) 4-methoxyamphetamine, some trade or other names:
             377      4-methoxy-.-methylphenethylamine; paramethoxyamphetamine, PMA;
             378          (G) 5-methoxy-3,4-methylenedioxyamphetamine;
             379          (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
             380      4-methyl-2,5-dimethoxy-.-methylphenethylamine; "DOM"; and "STP";
             381          (I) 3,4-methylenedioxy amphetamine;
             382          (J) 3,4-methylenedioxymethamphetamine (MDMA);
             383          (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
             384      alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
             385          (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
             386      N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
             387          (M) 3,4,5-trimethoxy amphetamine;
             388          (N) Bufotenine, some trade and other names:
             389      3-(.-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
             390      N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
             391          (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
             392          (P) Dimethyltryptamine, some trade or other names: DMT;
             393          (Q) Ibogaine, some trade and other names:
             394      7-Ethyl-6,6.,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
             395      [5,4-b] indole; Tabernanthe iboga;
             396          (R) Lysergic acid diethylamide;
             397          (S) Marijuana;
             398          (T) Mescaline;
             399          (U) Parahexyl, some trade or other names:


             400      3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
             401          (V) Peyote, meaning all parts of the plant presently classified botanically as
             402      Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
             403      any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
             404      preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
             405          (W) N-ethyl-3-piperidyl benzilate;
             406          (X) N-methyl-3-piperidyl benzilate;
             407          (Y) Psilocybin;
             408          (Z) Psilocyn;
             409          (AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the
             410      plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
             411      and their isomers with similar chemical structure and pharmacological activity such as the
             412      following: .1 cis or trans tetrahydrocannabinol, and their optical isomers .6 cis or trans
             413      tetrahydrocannabinol, and their optical isomers .3,4 cis or trans tetrahydrocannabinol, and its
             414      optical isomers, and since nomenclature of these substances is not internationally standardized,
             415      compounds of these structures, regardless of numerical designation of atomic positions
             416      covered;
             417          (BB) Ethylamine analog of phencyclidine, some trade or other names:
             418      N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
             419      N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
             420          (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
             421      1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
             422          (DD) Thiophene analog of phencyclidine, some trade or other names:
             423      1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
             424          (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
             425          (iv) Unless specifically excepted or unless listed in another schedule, any material
             426      compound, mixture, or preparation which contains any quantity of the following substances
             427      having a depressant effect on the central nervous system, including its salts, isomers, and salts
             428      of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
             429      specific chemical designation:
             430          (A) Mecloqualone; and


             431          (B) Methaqualone.
             432          (v) Any material, compound, mixture, or preparation containing any quantity of the
             433      following substances having a stimulant effect on the central nervous system, including their
             434      salts, isomers, and salts of isomers:
             435          (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
             436      4,5-dihydro-5-phenyl-2-oxazolamine;
             437          (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
             438      alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
             439          (C) Fenethylline;
             440          (D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
             441      alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
             442      alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
             443      methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
             444      optical isomers;
             445          (E) (.)cis-4-methylaminorex ((.)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
             446          (F) N-ethylamphetamine; and
             447          (G) N,N-dimethylamphetamine, also known as
             448      N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
             449          (vi) Any material, compound, mixture, or preparation which contains any quantity of
             450      the following substances, including their optical isomers, salts, and salts of isomers, subject to
             451      temporary emergency scheduling:
             452          (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
             453          (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
             454          (vii) Unless specifically excepted or unless listed in another schedule, any material,
             455      compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
             456      (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
             457          (b) Schedule II:
             458          (i) Unless specifically excepted or unless listed in another schedule, any of the
             459      following substances whether produced directly or indirectly by extraction from substances of
             460      vegetable origin, or independently by means of chemical synthesis, or by a combination of
             461      extraction and chemical synthesis:


             462          (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
             463      opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,
             464      and their respective salts, but including:
             465          (I) Raw opium;
             466          (II) Opium extracts;
             467          (III) Opium fluid;
             468          (IV) Powdered opium;
             469          (V) Granulated opium;
             470          (VI) Tincture of opium;
             471          (VII) Codeine;
             472          (VIII) Ethylmorphine;
             473          (IX) Etorphine hydrochloride;
             474          (X) Hydrocodone;
             475          (XI) Hydromorphone;
             476          (XII) Metopon;
             477          (XIII) Morphine;
             478          (XIV) Oxycodone;
             479          (XV) Oxymorphone; and
             480          (XVI) Thebaine;
             481          (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
             482      identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
             483      substances may not include the isoquinoline alkaloids of opium;
             484          (C) Opium poppy and poppy straw;
             485          (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
             486      any salt, compound, derivative, or preparation which is chemically equivalent or identical with
             487      any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
             488      and salts of isomers and derivatives, whether derived from the coca plant or synthetically
             489      produced, except the substances may not include decocainized coca leaves or extraction of coca
             490      leaves, which extractions do not contain cocaine or ecgonine; and
             491          (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
             492      liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.


             493          (ii) Unless specifically excepted or unless listed in another schedule, any of the
             494      following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
             495      ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
             496      chemical designation, except dextrorphan and levopropoxyphene:
             497          (A) Alfentanil;
             498          (B) Alphaprodine;
             499          (C) Anileridine;
             500          (D) Bezitramide;
             501          (E) Bulk dextropropoxyphene (nondosage forms);
             502          (F) Carfentanil;
             503          (G) Dihydrocodeine;
             504          (H) Diphenoxylate;
             505          (I) Fentanyl;
             506          (J) Isomethadone;
             507          (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
             508      levomethadyl acetate, or LAAM;
             509          (L) Levomethorphan;
             510          (M) Levorphanol;
             511          (N) Metazocine;
             512          (O) Methadone;
             513          (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
             514          (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
             515      acid;
             516          (R) Pethidine (meperidine);
             517          (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
             518          (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
             519          (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
             520          (V) Phenazocine;
             521          (W) Piminodine;
             522          (X) Racemethorphan;
             523          (Y) Racemorphan;


             524          (Z) Remifentanil; and
             525          (AA) Sufentanil.
             526          (iii) Unless specifically excepted or unless listed in another schedule, any material,
             527      compound, mixture, or preparation which contains any quantity of the following substances
             528      having a stimulant effect on the central nervous system:
             529          (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
             530          (B) Methamphetamine, its salts, isomers, and salts of its isomers;
             531          (C) Phenmetrazine and its salts; and
             532          (D) Methylphenidate.
             533          (iv) Unless specifically excepted or unless listed in another schedule, any material,
             534      compound, mixture, or preparation which contains any quantity of the following substances
             535      having a depressant effect on the central nervous system, including its salts, isomers, and salts
             536      of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
             537      specific chemical designation:
             538          (A) Amobarbital;
             539          (B) Glutethimide;
             540          (C) Pentobarbital;
             541          (D) Phencyclidine;
             542          (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
             543      1-piperidinocyclohexanecarbonitrile (PCC); and
             544          (F) Secobarbital.
             545          (v) Unless specifically excepted or unless listed in another schedule, any material,
             546      compound, mixture, or preparation which contains any quantity of Phenylacetone.
             547          Some of these substances may be known by trade or other names: phenyl-2-propanone,
             548      P2P; benzyl methyl ketone, methyl benzyl ketone.
             549          (vi) Nabilone, another name for nabilone:
             550      (.)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
             551      6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
             552          (c) Schedule III:
             553          (i) Unless specifically excepted or unless listed in another schedule, any material,
             554      compound, mixture, or preparation which contains any quantity of the following substances


             555      having a stimulant effect on the central nervous system, including its salts, isomers whether
             556      optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,
             557      and salts of isomers is possible within the specific chemical designation:
             558          (A) Those compounds, mixtures, or preparations in dosage unit form containing any
             559      stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
             560      listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
             561      Code of Federal Regulations, and any other drug of the quantitive composition shown in that
             562      list for those drugs or which is the same except that it contains a lesser quantity of controlled
             563      substances;
             564          (B) Benzphetamine;
             565          (C) Chlorphentermine;
             566          (D) Clortermine; and
             567          (E) Phendimetrazine.
             568          (ii) Unless specifically excepted or unless listed in another schedule, any material,
             569      compound, mixture, or preparation which contains any quantity of the following substances
             570      having a depressant effect on the central nervous system:
             571          (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
             572      pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
             573      which are not listed in any schedule;
             574          (B) Any suppository dosage form containing amobarbital, secobarbital, or
             575      pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
             576      Administration for marketing only as a suppository;
             577          (C) Any substance which contains any quantity of a derivative of barbituric acid or any
             578      salt of any of them;
             579          (D) Chlorhexadol;
             580          (E) Buprenorphine;
             581          (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
             582      isomers, and salts of isomers, for which an application is approved under the federal Food,
             583      Drug, and Cosmetic Act, Section 505;
             584          (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
             585      . -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;


             586          (H) Lysergic acid;
             587          (I) Lysergic acid amide;
             588          (J) Methyprylon;
             589          (K) Sulfondiethylmethane;
             590          (L) Sulfonethylmethane;
             591          (M) Sulfonmethane; and
             592          (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
             593      tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
             594      2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
             595      4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
             596      flupyrazapon.
             597          (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
             598      U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
             599      (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
             600      (-)-delta-9-(trans)-tetrahydrocannabinol.
             601          (iv) Nalorphine.
             602          (v) Unless specifically excepted or unless listed in another schedule, any material,
             603      compound, mixture, or preparation containing limited quantities of any of the following
             604      narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
             605          (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
             606      milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of
             607      opium;
             608          (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
             609      milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
             610      therapeutic amounts;
             611          (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
             612      than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline
             613      alkaloid of opium;
             614          (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
             615      than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             616      recognized therapeutic amounts;


             617          (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
             618      milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
             619      therapeutic amounts;
             620          (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
             621      than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             622      recognized therapeutic amounts;
             623          (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
             624      more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             625      recognized therapeutic amounts; and
             626          (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
             627      one or more active, non-narcotic ingredients in recognized therapeutic amounts.
             628          (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids
             629      including any of the following or any isomer, ester, salt, or derivative of the following that
             630      promotes muscle growth:
             631          (A) Boldenone;
             632          (B) Chlorotestosterone (4-chlortestosterone);
             633          (C) Clostebol;
             634          (D) Dehydrochlormethyltestosterone;
             635          (E) Dihydrotestosterone (4-dihydrotestosterone);
             636          (F) Drostanolone;
             637          (G) Ethylestrenol;
             638          (H) Fluoxymesterone;
             639          (I) Formebulone (formebolone);
             640          (J) Mesterolone;
             641          (K) Methandienone;
             642          (L) Methandranone;
             643          (M) Methandriol;
             644          (N) Methandrostenolone;
             645          (O) Methenolone;
             646          (P) Methyltestosterone;
             647          (Q) Mibolerone;


             648          (R) Nandrolone;
             649          (S) Norethandrolone;
             650          (T) Oxandrolone;
             651          (U) Oxymesterone;
             652          (V) Oxymetholone;
             653          (W) Stanolone;
             654          (X) Stanozolol;
             655          (Y) Testolactone;
             656          (Z) Testosterone; and
             657          (AA) Trenbolone.
             658          Anabolic steroids expressly intended for administration through implants to cattle or
             659      other nonhuman species, and approved by the Secretary of Health and Human Services for use,
             660      may not be classified as a controlled substance.
             661          (d) Schedule IV:
             662          (i) Unless specifically excepted or unless listed in another schedule, any material,
             663      compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
             664      less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
             665          (ii) Unless specifically excepted or unless listed in another schedule, any material,
             666      compound, mixture, or preparation which contains any quantity of the following substances,
             667      including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
             668      salts of isomers is possible within the specific chemical designation:
             669          (A) Alprazolam;
             670          (B) Barbital;
             671          (C) Bromazepam;
             672          (D) Butorphanol;
             673          (E) Camazepam;
             674          (F) Chloral betaine;
             675          (G) Chloral hydrate;
             676          (H) Chlordiazepoxide;
             677          (I) Clobazam;
             678          (J) Clonazepam;


             679          (K) Clorazepate;
             680          (L) Clotiazepam;
             681          (M) Cloxazolam;
             682          (N) Delorazepam;
             683          (O) Diazepam;
             684          (P) Dichloralphenazone;
             685          (Q) Estazolam;
             686          (R) Ethchlorvynol;
             687          (S) Ethinamate;
             688          (T) Ethyl loflazepate;
             689          (U) Fludiazepam;
             690          (V) Flunitrazepam;
             691          (W) Flurazepam;
             692          (X) Halazepam;
             693          (Y) Haloxazolam;
             694          (Z) Ketazolam;
             695          (AA) Loprazolam;
             696          (BB) Lorazepam;
             697          (CC) Lormetazepam;
             698          (DD) Mebutamate;
             699          (EE) Medazepam;
             700          (FF) Meprobamate;
             701          (GG) Methohexital;
             702          (HH) Methylphenobarbital (mephobarbital);
             703          (II) Midazolam;
             704          (JJ) Nimetazepam;
             705          (KK) Nitrazepam;
             706          (LL) Nordiazepam;
             707          (MM) Oxazepam;
             708          (NN) Oxazolam;
             709          (OO) Paraldehyde;


             710          (PP) Pentazocine;
             711          (QQ) Petrichloral;
             712          (RR) Phenobarbital;
             713          (SS) Pinazepam;
             714          (TT) Prazepam;
             715          (UU) Quazepam;
             716          (VV) Temazepam;
             717          (WW) Tetrazepam;
             718          (XX) Triazolam;
             719          (YY) Zaleplon; and
             720          (ZZ) Zolpidem.
             721          (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
             722      any quantity of the following substances, including its salts, isomers whether optical, position,
             723      or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
             724      isomers is possible.
             725          (iv) Unless specifically excepted or unless listed in another schedule, any material,
             726      compound, mixture, or preparation which contains any quantity of the following substances
             727      having a stimulant effect on the central nervous system, including its salts, isomers whether
             728      optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
             729      isomers, and salts of isomers is possible within the specific chemical designation:
             730          (A) Cathine ((+)-norpseudoephedrine);
             731          (B) Diethylpropion;
             732          (C) Fencamfamine;
             733          (D) Fenproprex;
             734          (E) Mazindol;
             735          (F) Mefenorex;
             736          (G) Modafinil;
             737          (H) Pemoline, including organometallic complexes and chelates thereof;
             738          (I) Phentermine;
             739          (J) Pipradrol;
             740          (K) Sibutramine; and


             741          (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
             742          (v) Unless specifically excepted or unless listed in another schedule, any material,
             743      compound, mixture, or preparation which contains any quantity of dextropropoxyphene
             744      (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
             745          (e) Schedule V:
             746          (i) Any compound, mixture, or preparation containing any of the following limited
             747      quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid,
             748      which includes one or more non-narcotic active medicinal ingredients in sufficient proportion
             749      to confer upon the compound, mixture, or preparation valuable medicinal qualities other than
             750      those possessed by the narcotic drug alone:
             751          [(i)] (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
             752          [(ii)] (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
             753      grams;
             754          [(iii)] (C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
             755      grams;
             756          [(iv)] (D) not more than 2.5 milligrams of diphenoxylate and not less than 25
             757      micrograms of atropine sulfate per dosage unit;
             758          [(v)] (E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
             759          [(vi)] (F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
             760      atropine sulfate per dosage unit; [and]
             761          [(vii)] (G) unless specifically exempted or excluded or unless listed in another
             762      schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having
             763      a stimulant effect on the central nervous system, including its salts, isomers, and salts of
             764      isomers[.]; and
             765          (H) ephedrine, pseudoephedrine, norpseudoephedrine, and phenylpropanolamine.
             766          (ii) Notwithstanding Subsections 58-37-2 (1)(m), 58-37-4 (e)(ii), and 58-37-7.5 (4),
             767      products containing ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine
             768      and that are intended for lawful use in the diagnosis, cure, mitigation, treatment, or prevention
             769      of disease may be purchased, sold, or transferred as an over-the-counter medication without a
             770      prescription if:
             771          (A) dispensed by a person licensed under Title 58, Chapter 17b, Pharmacy Practice


             772      Act; and
             773          (B) recorded in the controlled substance database created in Section 58-37-7.5 .
             774          Section 3. Section 58-37-7.5 is amended to read:
             775           58-37-7.5. Controlled substance database -- Pharmacy reporting requirements --
             776      Access -- Penalties.
             777          (1) As used in this section:
             778          (a) "Database" means the controlled substance database created in this section.
             779          (b) "Database manager" means the person responsible for operating the database, or his
             780      designee.
             781          (c) "Division" means the Division of Occupational and Professional Licensing created
             782      in Section 58-1-103 .
             783          (d) "Health care facility" has the same definition as in Section 26-21-2 .
             784          (e) "Pharmacy or pharmaceutical facility" has the same definition as in Section
             785      58-17b-102 .
             786          (2) (a) There is created within the division a controlled substance database.
             787          (b) The division shall administer and direct the functioning of the database in
             788      accordance with this section. The division may under state procurement laws contract with
             789      another state agency or private entity to establish, operate, or maintain the database. The
             790      division in collaboration with the board shall determine whether to operate the database within
             791      the division or contract with another entity to operate the database, based on an analysis of
             792      costs and benefits.
             793          (c) The purpose of the database is to contain data as described in this section regarding
             794      every prescription for a controlled substance dispensed in the state to any person other than an
             795      inpatient in a licensed health care facility.
             796          (d) Data required by this section shall be submitted in compliance with this section to
             797      the manager of the database by the pharmacist in charge of the drug outlet where the controlled
             798      substance is dispensed.
             799          (3) The Utah State Board of Pharmacy created in Section 58-17b-201 shall advise the
             800      division regarding:
             801          (a) establishing, maintaining, and operating the database;
             802          (b) access to the database and how access is obtained; and


             803          (c) control of information contained in the database.
             804          (4) The pharmacist in charge shall, regarding each controlled substance dispensed by a
             805      pharmacist under his supervision other than those dispensed for an inpatient at a health care
             806      facility, submit to the manager of the database the following information, by a procedure and in
             807      a format established by the division:
             808          (a) name of the prescribing practitioner;
             809          (b) date of the prescription;
             810          (c) date the prescription was filled;
             811          (d) name of the person for whom the prescription was written;
             812          (e) positive identification of the person receiving the prescription, including the type of
             813      identification and any identifying numbers on the identification;
             814          (f) name of the controlled substance;
             815          (g) quantity of controlled substance prescribed;
             816          (h) strength of controlled substance;
             817          (i) quantity of controlled substance dispensed;
             818          (j) dosage quantity and frequency as prescribed;
             819          (k) name of drug outlet dispensing the controlled substance;
             820          (l) name of pharmacist dispensing the controlled substance; and
             821          (m) other relevant information as required by division rule.
             822          (5) The division shall maintain the database in an electronic file or by other means
             823      established by the division to facilitate use of the database for identification of:
             824          (a) prescribing practices and patterns of prescribing and dispensing controlled
             825      substances;
             826          (b) practitioners prescribing controlled substances in an unprofessional or unlawful
             827      manner;
             828          (c) individuals receiving prescriptions for controlled substances from licensed
             829      practitioners, and who subsequently obtain dispensed controlled substances from a drug outlet
             830      in quantities or with a frequency inconsistent with generally recognized standards of dosage for
             831      that controlled substance; and
             832          (d) individuals presenting forged or otherwise false or altered prescriptions for
             833      controlled substances to a pharmacy.


             834          (6) (a) The division shall by rule establish the electronic format in which the
             835      information required under this section shall be submitted to the administrator of the database.
             836          (b) Notwithstanding the requirements of Subsection (4), the division shall establish by
             837      rule, in accordance with Title 63, Chapter 46a, Utah Administrative Rulemaking Act, database
             838      reporting requirements for controlled substances that may be dispensed without a prescription
             839      under this chapter.
             840          [(b)] (c) The division shall ensure the database system records and maintains for
             841      reference:
             842          (i) identification of each person who requests or receives information from the
             843      database;
             844          (ii) the information provided to each person; and
             845          (iii) the date and time the information is requested or provided.
             846          (7) The division shall make rules to:
             847          (a) effectively enforce the limitations on access to the database as described in
             848      Subsection (8); and
             849          (b) establish standards and procedures to ensure accurate identification of individuals
             850      requesting information or receiving information without request from the database.
             851          (8) The manager of the database shall make information in the database available only
             852      to the following persons, and in accordance with the limitations stated and division rules:
             853          (a) personnel of the division specifically assigned to conduct investigations related to
             854      controlled substances laws under the jurisdiction of the division;
             855          (b) authorized division personnel engaged in analysis of controlled substance
             856      prescription information as a part of the assigned duties and responsibilities of their
             857      employment;
             858          (c) employees of the Department of Health whom the director of the Department of
             859      Health assigns to conduct scientific studies regarding the use or abuse of controlled substances,
             860      provided that the identity of the individuals and pharmacies in the database are confidential and
             861      are not disclosed in any manner to any individual who is not directly involved in the scientific
             862      studies;
             863          (d) a licensed practitioner having authority to prescribe controlled substances, to the
             864      extent the information relates specifically to a current patient of the practitioner, to whom the


             865      practitioner is prescribing or considering prescribing any controlled substance;
             866          (e) a licensed pharmacist having authority to dispense controlled substances to the
             867      extent the information relates specifically to a current patient to whom that pharmacist is
             868      dispensing or considering dispensing any controlled substance;
             869          (f) federal, state, and local law enforcement authorities engaged as a specified duty of
             870      their employment in enforcing laws regulating controlled substances; and
             871          (g) an individual who is the recipient of a controlled substance prescription entered into
             872      the database, upon providing evidence satisfactory to the database manager that the individual
             873      requesting the information is in fact the person about whom the data entry was made.
             874          (9) Any person who knowingly and intentionally releases any information in the
             875      database in violation of the limitations under Subsection (8) is guilty of a third degree felony.
             876          (10) Any person who obtains or attempts to obtain information from the database by
             877      misrepresentation or fraud is guilty of a third degree felony.
             878          (11) (a) A person may not knowingly and intentionally use, release, publish, or
             879      otherwise make available to any other person or entity any information obtained from the
             880      database for any purpose other than those specified in Subsection (8). Each separate violation
             881      of this Subsection (11) is a third degree felony and is also subject to a civil penalty not to
             882      exceed $5,000.
             883          (b) The procedure for determining a civil violation of this Subsection (11) shall be in
             884      accordance with Section 58-1-108 , regarding adjudicative proceedings within the division.
             885          (c) Civil penalties assessed under this Subsection (11) shall be deposited in the General
             886      Fund as a dedicated credit to be used by the division under Subsection 58-37-7.7 (1).
             887          (12) (a) The failure of a pharmacist in charge to submit information to the database as
             888      required under this section after the division has submitted a specific written request for the
             889      information or when the division determines the individual has a demonstrable pattern of
             890      failing to submit the information as required is grounds for the division to take the following
             891      actions in accordance with Section 58-1-401 :
             892          (i) refuse to issue a license to the individual;
             893          (ii) refuse to renew the individual's license;
             894          (iii) revoke, suspend, restrict, or place on probation the license;
             895          (iv) issue a public or private reprimand to the individual;


             896          (v) issue a cease and desist order; and
             897          (vi) impose a civil penalty of not more than $1,000 for each dispensed prescription
             898      regarding which the required information is not submitted.
             899          (b) Civil penalties assessed under Subsection (12)(a)(vi) shall be deposited in the
             900      General Fund as a dedicated credit to be used by the division under Subsection 58-37-7.7 (1).
             901          (c) The procedure for determining a civil violation of this Subsection (12) shall be in
             902      accordance with Section 58-1-108 , regarding adjudicative proceedings within the division.
             903          (13) An individual who has submitted information to the database in accordance with
             904      this section may not be held civilly liable for having submitted the information.
             905          (14) All department and the division costs necessary to establish and operate the
             906      database shall be funded by appropriations from:
             907          (a) the Commerce Service Fund; and
             908          (b) the General Fund.
             909          (15) All costs associated with recording and submitting data as required in this section
             910      shall be assumed by the submitting pharmacy.
             911          Section 4. Effective date.
             912          This bill takes effect on January 1, 2008.




Legislative Review Note
    as of 1-22-07 2:35 PM


Office of Legislative Research and General Counsel


[Bill Documents][Bills Directory]